Barclays maintains Inspire Medical Systems at Underweight, lowers price target to $62 from $65

Barclays lowered its price target for Inspire Medical Systems to $62 from $65, maintaining an Underweight rating. This implies a 7.8% downside from the Nov 2 close of $67.21. Recent analyst targets range from $65 to $78.

Original reporting
Published Nov 3, 2026, 2:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Inspire Medical Systems at Underweight, lowers price target to $62 from $65 — source image
Decision brief

The 30-second read

$INSPBearishMed
01

Why it matters

The downgrade could trigger short-term selling and affect related peer valuations.

02

Market read

Analyst target cuts are a common catalyst for price movement in small-cap stocks.

03

What to watch

Potential upcoming product approvals or contract wins not yet reflected in the analyst note.

Relevance 5/10Novelty 5/10Timing: today

Background

Barclays' research note updates its valuation and rating for Inspire Medical Systems.

Company-level read

Ticker impact

$INSPBearishHigh confidence
Context

Barclays lowered its price target on Inspire Medical Systems to $62 from $65, maintaining an Underweight rating.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Target reduction signals weaker outlook, which typically leads to short-term sell pressure.

Market effects

May weigh on other medical device stocks as analysts reassess sector outlook.

Limited to U.S. biotech/medical device investors.

Low global impact.

Counterpoint

Some investors may view the target cut as an entry point if they believe the downgrade overstates risks.

Key entities

  • Barclays

    Issued the price target reduction.

  • Inspire Medical Systems

    Subject of the analyst downgrade.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.